Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Allarity Therapeutics, Inc. (Nasdaq: ALLR), a Delaware corporation, filed this Current Report on Form 8-K on April 22, 2022, regarding an event dated April 20, 2022. The Company is classified as an emerging growth company.
Key Financial Metrics
This filing is a notice of delisting risk and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
- Delisting Notice: On April 20, 2022, the Company received a notice from The NASDAQ Stock Market LLC stating it is no longer in compliance with Listing Rule 5250(c)(1).
- Reason for Non-Compliance: The Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
- Immediate Impact: The notice has no immediate effect on the listing of the Company's common stock on NASDAQ.
Outlook, Management Commentary, and Risks
The Company intends to file its Form 10-K as soon as practicable within the 60-day compliance period ending June 19, 2022. If the Company fails to file by this date, it intends to submit a plan to regain compliance. If NASDAQ accepts this plan, the Company may be granted up to 180 days from the original due date (until October 17, 2022) to regain compliance. If the plan is rejected, the Company retains the right to appeal to a NASDAQ Hearings Panel.
Key Facts for Investor Verification
- Verify the current status of the Form 10-K for the fiscal year ended December 31, 2021.
- Monitor whether the Company files the 10-K by the June 19, 2022 deadline.
- Check for any subsequent announcements regarding the acceptance or rejection of a compliance plan by NASDAQ.
- Review the attached press release (Exhibit 99.1) for additional details on the Company's operational status.